TNF Pharmaceuticals, Inc. financial data

Symbol
TNFA on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
855 N. Wolfe Street, Suite 601, Baltimore, MD
State of incorporation
DE
Fiscal year end
December 31
Former names
MyMD Pharmaceuticals, Inc. (to 7/1/2024), Akers Biosciences, Inc. (to 4/16/2021), Akers Biosciences Inc (to 4/11/2017)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 159 % -55.2%
Debt-to-equity 108 % +59%
Return On Equity -242 % -506%
Return On Assets -114 % -394%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.37M shares -95.3%
Common Stock, Shares, Outstanding 2.47M shares -94.7%
Entity Public Float 63M USD -10.4%
Common Stock, Value, Issued 112M USD +3.92%
Weighted Average Number of Shares Outstanding, Basic 2.42M shares +54.4%
Weighted Average Number of Shares Outstanding, Diluted 2.42M shares -69.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.27M USD -28.6%
General and Administrative Expense 4.43M USD -18.3%
Operating Income (Loss) -12.9M USD +19.6%
Nonoperating Income (Expense) -10.8M USD -201%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -23.7M USD -340%
Net Income (Loss) Attributable to Parent -23.7M USD -340%
Earnings Per Share, Basic -13.5 USD/shares +3.49%
Earnings Per Share, Diluted -12.1 USD/shares -400%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.19M USD +300%
Marketable Securities, Current 9.45M USD +15.6%
Assets, Current 12M USD +23.5%
Operating Lease, Right-of-Use Asset 18.3K USD -79.9%
Goodwill 10.5M USD 0%
Assets 24M USD +10.2%
Accounts Payable, Current 4.16M USD +105%
Accrued Liabilities, Current 455K USD -33.6%
Liabilities, Current 6.99M USD +22.7%
Operating Lease, Liability, Noncurrent 20.5K USD -78%
Liabilities 6.99M USD +22.3%
Retained Earnings (Accumulated Deficit) -126M USD -29.8%
Stockholders' Equity Attributable to Parent 16.8M USD +8.24%
Liabilities and Equity 24M USD +10.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.91M USD +51.9%
Net Cash Provided by (Used in) Financing Activities -1.28M USD -109%
Net Cash Provided by (Used in) Investing Activities 732K USD
Common Stock, Shares Authorized 250M shares -50%
Common Stock, Shares, Issued 2.47M shares -94.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.46M USD -338%
Deferred Tax Assets, Valuation Allowance 30.1M USD -12.1%
Operating Lease, Liability 18.3K USD -80.4%
Lessee, Operating Lease, Liability, to be Paid 18.9K USD -81%
Operating Lease, Liability, Current 18.3K USD -74.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 8.1K USD -89.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 615 USD -90.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.81K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.5M USD +1.22%
Preferred Stock, Shares Authorized 50M shares 0%
Operating Lease, Payments 9.34K USD -48.8%
Additional Paid in Capital 143M USD
Share-based Payment Arrangement, Expense 299K USD +1401%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares